As the European market experiences a modest upswing, with the pan-European STOXX Europe 600 Index rising by 1.40% amid hopes for lower U.S. borrowing costs, investors are keenly observing growth opportunities within this region. In such an environment, stocks characterized by significant insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the company's operations and potential for sustained growth.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 11.8% | 44.2% |
| MedinCell (ENXTPA:MEDCL) | 13.9% | 91% |
| Marinomed Biotech (WBAG:MARI) | 29.7% | 20.2% |
| KebNi (OM:KEBNI B) | 38.3% | 63.7% |
| Elliptic Laboratories (OB:ELABS) | 24.4% | 80.6% |
| CTT Systems (OM:CTT) | 17.5% | 37.9% |
| Circus (XTRA:CA1) | 24.7% | 72.6% |
| CD Projekt (WSE:CDR) | 29.7% | 39.5% |
| Bonesupport Holding (OM:BONEX) | 10.4% | 59.7% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 64.6% |
Underneath we present a selection of stocks filtered out by our screen.
Oryzon Genomics (BME:ORY)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €218.59 million.
Operations: The company generates revenue of €7.47 million from its biotechnology segment, which involves the discovery and development of epigenetics-based therapeutics for cancer and CNS disorders.
Insider Ownership: 17.2%
Earnings Growth Forecast: 58.9% p.a.
Oryzon Genomics demonstrates significant growth potential, with revenue forecasted to grow 56% annually, outpacing the Spanish market. Despite recent volatility and a net loss of €1.59 million in H1 2025, the company is poised to become profitable within three years. Recent EMA approval for a Phase Ib trial of iadademstat in sickle cell disease highlights its innovative pipeline. High insider ownership aligns management interests with shareholders, bolstering confidence amidst ongoing clinical developments.
- Take a closer look at Oryzon Genomics' potential here in our earnings growth report.
- Our expertly prepared valuation report Oryzon Genomics implies its share price may be too high.
Devyser Diagnostics (OM:DVYSR)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing in areas such as hereditary diseases, oncology, and post-transplantation monitoring across multiple regions globally; the company has a market cap of approximately SEK2.45 billion.
Operations: The company's revenue primarily comes from its diagnostic kits and equipment segment, which generated SEK235.10 million.
Insider Ownership: 35.1%
Earnings Growth Forecast: 114.4% p.a.
Devyser Diagnostics is set for robust growth, with revenue expected to increase by 27.9% annually, surpassing the Swedish market. The company reported a net income of SEK 1.3 million in Q2 2025 compared to a significant loss last year, indicating improved financial health. Recent product launches, including advanced genomic blood typing and HLA loss detection assays, enhance its research capabilities. High insider ownership suggests aligned management interests as Devyser aims for profitability within three years.
- Navigate through the intricacies of Devyser Diagnostics with our comprehensive analyst estimates report here.
- Upon reviewing our latest valuation report, Devyser Diagnostics' share price might be too optimistic.
Volati (OM:VOLO)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Volati AB (publ) is a private equity firm that focuses on growth capital, buyouts, and add-on acquisitions in mature and middle-market companies, with a market cap of SEK8.77 billion.
Operations: The company's revenue segments include Salix Group at SEK3.89 billion, Ettiketto Group at SEK1.09 billion, and Industry (excluding Ettiketto) at SEK3.27 billion.
Insider Ownership: 28.9%
Earnings Growth Forecast: 32.3% p.a.
Volati shows promising growth potential, with earnings forecasted to grow significantly at 32.3% annually, outpacing the Swedish market. Despite a slower revenue growth of 5.8%, recent Q2 results indicate steady financial performance with sales reaching SEK 2.32 billion and net income improving to SEK 133 million. Insider activity reflects confidence, as more shares were bought than sold recently, although not substantially. The stock trades well below its estimated fair value, despite having a high debt level.
- Click here and access our complete growth analysis report to understand the dynamics of Volati.
- Insights from our recent valuation report point to the potential undervaluation of Volati shares in the market.
Summing It All Up
- Dive into all 220 of the Fast Growing European Companies With High Insider Ownership we have identified here.
- Ready To Venture Into Other Investment Styles? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Devyser Diagnostics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com